Drug

Kelun Pharma's Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD's KEYTRUDA
ADC / XDCKelun Pharmaceutical

Kelun Pharma’s Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD’s KEYTRUDA

Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that a new indication application for sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) has been accepted for review by the Center for…

Joincare's LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty

Joincare’s LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty

Hengrui's Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care

Hengrui’s Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
GSK's Nucala Receives FDA Approval for COPD Treatment
GlaxoSmithKlineGSK

GSK’s Nucala Receives FDA Approval for COPD Treatment

Merck's Welireg Launched in China for Rare Genetic Disorder Treatment
Market launchMerck Sharp & Dohme

Merck’s Welireg Launched in China for Rare Genetic Disorder Treatment

NMPA Approves Bayer/Regeneron's Eylea HD for Wet AMD Treatment
BayerETR: BAYN

NMPA Approves Bayer/Regeneron’s Eylea HD for Wet AMD Treatment

Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025
Academic conferenceAscentage Pharma

Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025

Show More